Consultant Medical Oncologist & Medical Director
Onco Life Centre, Kuala Lumpur · Pantai Hospital KL
MBBS — University of Melbourne (1992)
FRACP — Royal Australasian College of Physicians (2002)
Experience — 30+ years clinical & research
Dr Christina Ng Van Tze, MBBS (Melb), FRACP, is a Consultant Medical Oncologist and Medical Director at Onco Life Centre, Kuala Lumpur — a specialist oncology clinic she founded in 2016.
Australian-trained at the University of Melbourne, Dr Christina completed her MBBS in 1992 and was selected by the Victorian Medical Oncology Training Group for Advanced Specialist Training in Medical Oncology in 2000. She earned Fellowship of the Royal Australasian College of Physicians (FRACP) in 2002 — the highest standard of specialist certification in Australia and New Zealand.
Before returning to Malaysia, Dr Christina served as a Consultant Medical Oncologist at St. Vincent’s and Mercy Private Hospital, Epworth Cancer Center, and Freemason’s Hospital in Melbourne. She was also a Medical Oncology Research Fellow at the Ludwig Institute for Cancer Research and the Austin Research Institute — two of Australia’s leading oncology research centres. Earlier in her training, she worked at the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital.
She returned to Malaysia in 2003 as Consultant Medical Oncologist and Senior Lecturer at University Malaya Medical Centre, and served as Honorary Consultant to the Clinical Research Centre, Ministry of Health Malaysia. Since founding Onco Life Centre in 2016, she has served as its Medical Director, leading a specialist team in personalised cancer treatment across all major cancer types.
Dr Christina’s clinical practice focuses on personalised cancer treatment planning, cancer genomics, targeted therapies, immunotherapy, and psycho-oncology support. Her primary cancer specialisations are:
Breast cancer · Colorectal cancer · Lung cancer · Nasopharyngeal cancer · Cancer genomics & targeted therapies · Psycho-oncology
Dr Christina has served as Principal Investigator across 17 international and national multi-centre trials, working with global pharmaceutical sponsors including Roche, GSK, Pfizer, Johnson & Johnson, Wyeth, Novartis, and Merck.
In 2005–2006, she authored and led Malaysia’s first investigator-initiated cancer trial — a Phase 2 study on nasopharyngeal carcinoma conducted across 8 government and private centres nationwide, supported by a Major Research Grant from the Ministry of Health Malaysia and Eli Lilly Pharmaceuticals USA.
Dr Christina is the Lead Author of the National Specialist Guidelines for Medical Oncology in Malaysia, adopted by the Ministry of Health Malaysia in 2006.
Her peer-reviewed research has been published in:
She has co-chaired and presented at the World Conference on Lung Cancer (IASLC) in Vienna (2016) and Yokohama (2017), and is a regular delegate at ESMO Congresses, most recently ESMO 2025 in Berlin.
In 2009, Dr Christina founded Empowered — The Cancer Advocacy Society of Malaysia.
Through Empowered, she has personally led colorectal cancer screening and treatment programs that have reached over 100,000 low-income Malaysians across Sentul, Selayang, Cheras, Ampang, and Lembah Subang. The society’s founding launch was officiated by the Director General of the Ministry of Health Malaysia.
She also authored My Journal — a multilingual patient resource available in English, Bahasa Malaysia, Mandarin, and Tamil — distributed free to over 10,000 cancer patients across government hospitals in Malaysia. Its second edition was officially launched by Malaysia’s Deputy Health Minister.
Dr Christina sees patients at Onco Life Centre, Bangsar South, Kuala Lumpur. To book a consultation or speak with our team about your care options:
Phone: +60 12-399 3260
Quick Summary Nearly all undifferentiated nasopharyngeal carcinoma (NPC) cases contain Epstein-Barr virus (EBV) genetic material. EBV viral proteins (LMP1, LMP2A) activate signalling pathways that drive cancer growth. NPC is rare globally but common in Southern China, Hong Kong, and Malaysia. Risk factors include salted fish consumption, family history, and genetic
Quick Summary Genetic testing for breast cancer checks for inherited BRCA1/BRCA2 mutations that increase cancer risk. Candidates include those with strong family history (breast cancer before age 50, ovarian, pancreatic, prostate, male breast cancer), Ashkenazi Jewish heritage, or early diagnosis. Testing involves blood/saliva, and results guide earlier screening and prevention
Quick Summary Targeted therapy drugs for liver cancer (especially hepatocellular carcinoma HCC) block cancer growth signals, slow tumor progression, and may help when surgery or transplant isn’t possible. Key types include tyrosine kinase inhibitors and monoclonal antibodies. Side effects may include fatigue, skin changes, high blood pressure. Targeted therapy is
Quick Summary: Colon Polyps and Colorectal Cancer Risk Colon polyps are small growths in the colon lining. Most are harmless, but some types (adenomatous polyps, sessile serrated polyps) may slowly turn into cancer over time. Risk factors include family history, inflammatory bowel disease, smoking, poor diet, and older age. Regular
Onco Life Centre is fully licensed as an Oncology Consultation and Treatment Centre (License No: 931401-00214-03/2024)
CONSULTANT MEDICAL ONCOLOGIST (NSR: 131550)
MBBS (MELB), FELLOW RACP (AUS)
CONSULTANT MEDICAL ONCOLOGIST (NSR: 124660)
MBBCH, BAO (IRE), MRCP (UK)
